- Nisoldipine
-
- $110.00/ kilograms
-
2023-12-29
- CAS:63675-72-9
- Min. Order: 1kilograms
- Purity: 99%
- Supply Ability: 5000 tons
- Nisoldipine
-
- $0.00 / 25KG
-
2023-09-05
- CAS:63675-72-9
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 50000KG/month
- Nisoldipine
-
- $500.00 / 1KG
-
2023-08-16
- CAS:63675-72-9
- Min. Order: 1KG
- Purity: >99%
- Supply Ability: 50000kg/Month
|
| | Nisoldipine Basic information |
| Product Name: | Nisoldipine | | Synonyms: | SYSCOR;Nisoldipin;1,4-DIHYDRO-2,6-DIMETHYL-4-(2-NITROPHENYL)-3,5-PYRIDINEDICARBOXYLIC ACID METHYL 2-METHYLPROPYL ESTER;Nisoldipine-d6;3-Isobutyl 5-Methyl 2,6-diMethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate;1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylic acid-3-methyl 5-(2-methylpropyl) ester;(±)-Isobutyl methyl 1,4-dihydro-2,6-dimethyl-4-(o-nitrophenyl)-3,5-pyridinedicarboxylate;1,4-Dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylic acid 3-methyl 5-isobutyl ester | | CAS: | 63675-72-9 | | MF: | C20H24N2O6 | | MW: | 388.41 | | EINECS: | 264-407-7 | | Product Categories: | Calcium channel;Cardiovascular APIs;Active Pharmaceutical Ingredients;All Inhibitors;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals | | Mol File: | 63675-72-9.mol |  |
| | Nisoldipine Chemical Properties |
| Melting point | 147-148°C | | Boiling point | 503.3±50.0 °C(Predicted) | | density | 1.205±0.06 g/cm3(Predicted) | | storage temp. | room temp | | solubility | DMSO: >10mg/mL | | pka | 2.67±0.70(Predicted) | | form | powder | | color | yellow | | Merck | 14,6565 | | InChIKey | VKQFCGNPDRICFG-UHFFFAOYSA-N | | CAS DataBase Reference | 63675-72-9(CAS DataBase Reference) | | NIST Chemistry Reference | Nisoldipine(63675-72-9) |
| Hazard Codes | Xn | | Risk Statements | 20/21/22 | | Safety Statements | 36 | | WGK Germany | 3 | | RTECS | US7975600 | | HS Code | 2933399090 |
| | Nisoldipine Usage And Synthesis |
| Description | Nisoldipine D4 is another long-acting dihydropyridine calcium channel blocker effective in the treatment of hypertension and angina pectoris. It is reported to have little or no cardiodepressive activity and to be more effective than nifedipine in reducing blood pressure in hypertensives. Nisoldipine has also been shown to be effective in the management of congestive heart failure. Reduction in dosage is necessary in patients with hepatic, but not renal impairment. | | Chemical Properties | Nisoldipine D4 is Light Tan Crystals | | Originator | Bayer AG (Germany) | | Uses | urease inhibitor | | Uses | Labeled Nisoldipine, intended for use as an internal standard for the quantification of Nisoldipine by GC- or LC-mass spectrometry. | | Uses | Dihydropyridine calcium channel blocker. Antihypertensive and antianginal | | Definition | ChEBI: A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a methoxycarbonyl group at position 3, an o-nitrophenyl group at position 4, and an isobutoxycarbonyl group at position 5. The racemate,
calcium channel blocker, is used in the treatment of hypertension and angina pectoris. | | Manufacturing Process | Boiling a solution of 12.7 g of 2'-nitrobenzylideneacetoacetic acid methyl ester
and 7.1 g of β-amino-crotonic acid isopropyl ester in 50 ml of methanol for 10
hours yielded 2,6-dimethyl-4-(2'-nitrophenyl)-1,4-dihydropyridine-3,5-
dicarboxylic acid 3-methyl ester-5-isopropyl ester of melting point 174°C
(from ethanol). Yield 48% of theory. | | Brand name | Sular (Sciele);Baymycard. | | Therapeutic Function | Coronary vasodilator | | General Description | In vitro studies show that the effects ofnisoldipine, 1,4-dihydro-2, 6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinecarboxylic acid methyl 2-methylpropyl ester(Sular), on contractile processes are selective, with greaterpotency on vascular smooth muscle than on cardiac muscle.
Nisoldipine is highly metabolized, with five majormetabolites identified. As with most of the dihydropyridines,the cytochrome P450 (CYP) 3A4 isozyme is mainlyresponsible for the metabolism of nisoldipine. The majorbiotransformation pathway appears to involve the hydroxylationof the isobutyl ester side chain. This particular metabolitehas approximately 10% of the activity of the parentcompound. | | Biochem/physiol Actions | L-type (CaV1.2) calcium channel blocker; dihydropyridine-type calcium channel blocker with selectivity for smooth muscle (CaV1.2b) over cardiac muscle (CaV1.2a). Arterial vasodilator and antihypertensive agent. |
| | Nisoldipine Preparation Products And Raw materials |
|